<DOC>
	<DOCNO>NCT00829764</DOCNO>
	<brief_summary>The objective single-dose , open-label , randomize , two-period crossover study compare rate absorption oral bioavailability test formulation doxycycline monohydrate 1 x 25 mg ( 5mL ) oral suspension manufacture IVAX Pharmaceuticals , Inc. distribute TEVA Pharmaceuticals USA equivalent oral dose commercially available reference product , Vibramycin MonohydrateÂ® manufacture Pfizer , Inc. follow overnight fast least 10 hour .</brief_summary>
	<brief_title>Doxycycline Monohydrate 25 mg ( 5mL ) Oral Suspension Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Inclusion Criteria All subject must satisfy follow criterion consider study participation : Subject must male nonpregnant , nonbreastfeeding female Subject must least 18 year age Subject must Body Mass Index ( BMI ) 18 30 kg/m2 , inclusive , body weight least 50 kg ( 110 lb ) Female Subjects surgically sterile least two year postmenopausal must agree utilize one follow form contraception , sexually active male partner , screen completion study . Approved forms contraception abstinence , double barrier ( condom spermicide , diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( 6 month minimum since vasectomy ) . Subject must voluntarily consent participate study provide write informed consent prior start studyspecific procedure . Subject willing able consume entire highcalorie , highfat breakfast meal designate timeframe require study period . Subject willing able remain study unit entire duration confinement period return outpatient visit . Exclusion Criteria Subjects may exclude follow : History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease condition , opinion Investigator would jeopardize safety subject validity study result . Has clinically significant abnormal find physical exam , medical history , ECG clinical laboratory result screen . History presence allergic adverse response doxycycline monohydrate relate drug . Has significantly abnormal diet four week precede first dose study medication . Has donate blood plasma within 30 day prior first dose study medication . Has participate another clinical trial within 30 day prior first dose study medication . Has use overthecounter ( OTC ) medication , include nutritional supplement , within 7 day prior first dose study medication . Has use prescription medication , include hormonal contraceptive hormonal replacement therapy , within 14 day prior first dose study medication . Has treat know enzyme alter drug barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . Has smoke use tobacco product within 90 day prior first dose study medication . Is female positive pregnancy test result . Has intolerance venipuncture . Has positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opiate ) Has history drug alcohol abuse . Has positive test , treat hepatitis B , hepatitis C HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>